Market Research Logo

Moderate Pain - Pipeline Review, H2 2015

Moderate Pain - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Moderate Pain - Pipeline Review, H2 2015’, provides an overview of the Moderate Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Moderate Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Moderate Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Moderate Pain Overview
Therapeutics Development
Pipeline Products for Moderate Pain - Overview
Pipeline Products for Moderate Pain - Comparative Analysis
Moderate Pain - Therapeutics under Development by Companies
Moderate Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Moderate Pain - Products under Development by Companies
Moderate Pain - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Amorsa Therapeutics Inc.
Charleston Laboratories, Inc.
Egalet Corporation
Elite Pharmaceuticals, Inc.
KemPharm, Inc.
Laboratorios Del Dr. Esteve S.A.
Lumosa Therapeutics Co., Ltd.
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
Pfizer Inc.
Purdue Pharma L.P.
Relmada Therapeutics, Inc.
Teva Pharmaceutical Industries Limited
Trevena, Inc.
Moderate Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(benzhydrocodone hydrochloride + acetaminophen) IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(celecoxib + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(dexketoprofen + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(hydrocodone bitartrate + acetaminophen) IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CL-108 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLH-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLH-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Egalet-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketamine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levorphanol tartrate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
meloxicam ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
morphine sulfate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-181 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OLT-1177 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxycodone hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxycodone hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV-734 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-116517 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moderate Pain - Recent Pipeline Updates
Moderate Pain - Dormant Projects
Moderate Pain - Discontinued Products
Moderate Pain - Product Development Milestones
Featured News & Press Releases
Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Moderate Pain, H2 2015
Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Moderate Pain - Pipeline by Amorsa Therapeutics Inc., H2 2015
Moderate Pain - Pipeline by Charleston Laboratories, Inc., H2 2015
Moderate Pain - Pipeline by Egalet Corporation, H2 2015
Moderate Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2015
Moderate Pain - Pipeline by KemPharm, Inc., H2 2015
Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
Moderate Pain - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
Moderate Pain - Pipeline by Nektar Therapeutics, H2 2015
Moderate Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2015
Moderate Pain - Pipeline by Pain Therapeutics, Inc., H2 2015
Moderate Pain - Pipeline by Pfizer Inc., H2 2015
Moderate Pain - Pipeline by Purdue Pharma L.P., H2 2015
Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015
Moderate Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Moderate Pain - Pipeline by Trevena, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Moderate Pain Therapeutics - Recent Pipeline Updates, H2 2015
Moderate Pain - Dormant Projects, H2 2015
Moderate Pain - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Moderate Pain, H2 2015
Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report